EP1865060A1 - Facteur intermédiaire transcriptionel 2 - Google Patents

Facteur intermédiaire transcriptionel 2 Download PDF

Info

Publication number
EP1865060A1
EP1865060A1 EP07101726A EP07101726A EP1865060A1 EP 1865060 A1 EP1865060 A1 EP 1865060A1 EP 07101726 A EP07101726 A EP 07101726A EP 07101726 A EP07101726 A EP 07101726A EP 1865060 A1 EP1865060 A1 EP 1865060A1
Authority
EP
European Patent Office
Prior art keywords
tif2
seq
polypeptide
activity
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07101726A
Other languages
German (de)
English (en)
Other versions
EP1865060B1 (fr
Inventor
Pierre Chambon
Hinrich Gronemeyer
Johannes Voegel
Yves Lutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Bristol Myers Squibb Co
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Institut National de la Sante et de la Recherche Medicale INSERM
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Louis Pasteur Strasbourg I, Institut National de la Sante et de la Recherche Medicale INSERM, Bristol Myers Squibb Co filed Critical Centre National de la Recherche Scientifique CNRS
Publication of EP1865060A1 publication Critical patent/EP1865060A1/fr
Application granted granted Critical
Publication of EP1865060B1 publication Critical patent/EP1865060B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Definitions

  • the present invention relates to a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are screening methods for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, as well as TIF2 antibodies. Also provided are screening methods for identifying agonists and antagonists of TIF2 AD1 activation domain activity, as are provided screening methods for identifying agonists and antagonists of TIF2 AD2 activation domain activity.
  • TIF2 transcriptional intermediary factor-2
  • Activators that enhance the initiation of transcription by RNA polymerase B are composed of at least two functional domains: a DNA binding domain and an activating domain ( M. Ptashne, Nature 335:683-689 (1988 ); P.J. Mitchell et al., Science 245:371-378 (1989 )). These two domains are generally separable functional units and each can actually be interchanged with the complementary region of an unrelated activator, thereby creating functional chimeric activators ( S. Green et al., Nature 325:75-78 (1987 )).
  • GAL4 and GCN4 proteins activate transcription by binding to specific upstream activation sequence, which have many of the characteristics of higher eukaryotic enhancer elements ( K. Struhl, Cell 49:295-297 (1987 )).
  • the herpes simplex activator VP16 represents another type of activator, which activates transcription by binding to the DNA-bound octamer transcription factor rather than binding to the DNA directly ( T. Gerster et al., Proc. Natl. Acad. Sci. USA 85:6347-6351 (1988 )).
  • the nuclear receptor family which includes receptors for steroid hormones, thyroid hormones, vitamin D, and the vitamin A derivative retinoic acid, are also transcriptional enhancer factors which bind DNA directly in the presence of their cognate ligand by recognition of specific enhancer elements, i.e., hormone- or ligand-responsive elements ( R.M. Evans, Cell 240:889-895 (1988 )).
  • These cognate ligands tend to be small, hydrophobic molecules, including steroid hormones such as estrogen and progesterone, thyroid hormone, vitamin D, and various retinoids ( S. Halachmi et al., Science 264:1455-1458 (1994 ); Gronemeyer, H. and Laudet, V., Protein Profile 2:1173-1308 (1995 )).
  • NRs NRs
  • Adrenal steroids for example, such as cortisol and aldosterone
  • body homeostasis controlling glycogen and mineral metabolism
  • the sex hormones provoke the development and determination of the embryonic reproductive system, masculinize/feminize the brain at birth, control reproduction and related behavior in adults and are responsible for development of secondary sex characteristics.
  • Vitamin D is necessary for proper bone development and plays a critical role in calcium metabolism and bone differentiation.
  • aberrant production of these hormones has been associated with a broad spectrum of clinical disease, including cancer and similar pathologic conditions.
  • All NRs display a modular structure, with five to six distinct regions, termed A-F.
  • the N-terminal A/B region contains the activation function AF-1, which can activate transcription constitutively.
  • Region C encompasses the DNA binding domain (DBD), which recognizes cognate cis -acting elements.
  • Region E contains the ligand-binding domain (LBD), a dimerization surface and the ligand-dependent transcriptional activation function AF-2 (reviewed in Mangelsdorft, D.J. et al., Cell 83:835-839 (1995a ); Mangelsdorft & Evans, Cell 83:841-850 (1995b ); Beato, M.
  • Yeast activators GAL4 and GCN4 and herpes simplex VP16 all contain activation domains that are composed of acidic stretches of amino acids, which may act by forming amphipathic ⁇ helices ( I.A. Hope et al., Cell 46:885-894 (1986 ); J. Ma et al., Cell 48:847-853 (1987 ); E. Giniger et al., Nature 330:670-672 (1987 ); S.J. Triezenberg et al., Genes Dev. 2:718-729 (1988 )).
  • the activation functions of human Sp1 and CTF/NFI proteins contain glutamine- and proline-rich areas, respectively ( A.J. Courey et al., Cell 55:887-898 (1988 ); N. Mermod et al., Cell 58:741-753 (1989 )).
  • Studies with steroid hormone receptors have shown that both the N-terminal A/B domain and the C-terminal hormone binding domain (HBD) contain transcription activation functions (AFs) ( M.T. Bocquel et al., Nucl. Acids Res., 17:2581-2595 (1989 ); L. Tora et al., Cell 59:477-487 (1989 )).
  • hER human estrogen receptor
  • hGR human glucocorticoid receptor
  • AFs may activate transcription by interacting with different components of the basic initiation complex ( Bocquel et al., Nucl. Acids. Res. 17:2581-2595 (1989 ); Meyer et al., Cell 57:433-442 (1989 ); L. Tora et al., Cell 59:477-487 (1989 )).
  • TIFs transcriptional intermediary factors
  • TIFs for NR AF-2s have been characterized (see Chambon, P., FASEB J 10:940-954 (1996 ); Glass, C.K. et al., Current Opin. Cell Biol. 9:222-232 (1997 ); Horwitz, K.B. et al., Mol. Endocrinol. 10:1167-1177 (1996 ) for recent reviews).
  • LeDouarin, B. et al., EMBO J. 15:6701-6715 (1996 ) have demonstrated that a 10-amino acid fragment of TIF1 ⁇ is necessary and sufficient to mediate interaction with RXR in a ligand- and AF-2 integrity-dependent manner.
  • TIF1 ⁇ a LxxLLL (SEQ ID NO:13) motif, termed NR box, whose integrity is required for interaction with nuclear receptors, and pointed out that this motif is conserved in several other putative coactivators ( LeDouarin, B. et al., EMBO J. 15:6701-6715 (1996 )) Whereas TIF1 ⁇ and several other putative coactivators do not, or only very poorly, stimulate transactivation by NRs in transiently transfected mammalian cells, the TIF2/SRC-1 family ( O ⁇ ate, S.A. et al., Science 270:1354-1357 (1995 ); Voegel, J.J.
  • CBP/p300 can also interact directly with SRC-1 ( Kamei, Y. et al., Cell 85:403-414 (1996 ); Yao, T.P. et al., Proc. Natl. Acad. Sci. USA 93:10626-10631 (1996 )) and both factors have been shown to exert histone acetyltransferase activity ( Bannister & Kouzarides, Nature 384:641-643 (1996 ); Ogryzko, V.V. et al., Cell 87:953-959 (1996 )).
  • CBP/p300 can recruit p/CAF which is itself a nuclear histone acetyltransferase ( Yang, X.J. et al., Nature 382:319-324 (1996 )).
  • NRs apart from interacting with coactivators in a ligand-dependent manner, NRs have also been shown to interact, often in a ligand-independent fashion, directly or indirectly with components of the transcriptional machinery, suds as TFIIB, TBP, TAPs, or TFIIH (Baniahmad et al ., (1993)); Jacq, X. et al., Cell 79:107-117 (1994 ); Schulman, IG. et al., Mol. Cell. Biol.
  • Histone acetylation on its own is, however, insufficient for transcription activation (Wong et al ., (1997)), and a simultaneous or subsequent fourth event comprises the direct and/or indirect recruitment of elements of the transcription machinery (e.g., TFIB, TBP, TAFs, TFIIH; Jacq, X. et al., Cell 79:107-117 (1994 ); Schulman, IG. et al., Mol. Cell. Biol. 16:3807-3813 (1996 ); May, M. et al., EMBO J. 15:3093-3104 (1996 ); Mengus, G. et al., Genes & Dev. 11:1381-1395 (1997 )).
  • elements of the transcription machinery e.g., TFIB, TBP, TAFs, TFIIH; Jacq, X. et al., Cell 79:107-117 (1994 ); Schulman, IG. et al., Mol. Cell
  • TIF2 transcriptional intermediary factor 2
  • TIF2 has been shown to exhibit all the properties expected for a TIF/mediator of AF-2: it interacts directly with the LBDs of several NRs in an agonist- and AF-2-integrity-dependent manner in vitro and in vivo , harbours an autonomous AF, relieves NR autosquelching, and enhances the activity of NR AF-2s when overexpressed in mammalian cells.
  • the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding TIF2 whose amino acid sequence is shown in Figure 1 (SEQ ID NO:2) or a fragment thereof
  • the invention provides isolated nucleic acid molecules encoding TIF2 having an amino acid sequence as encoded by the cDNA deposited as ATCC Deposit No. 97612.
  • the invention further provides an isolated nucleic acid molecule that hybridizes under stringent conditions to the above-described nucleic acid molecules.
  • the present invention also relates to variants of the nucleic acid molecules of the present invention, which encode fragments, analogs or derivatives of the TIF2 protein, e . g ., polypeptides having at least one biological activity that is substantially similar to at least on biological activity of the TIF2 protein.
  • the present invention is further directed to isolated nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide.
  • Methods for generating nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide include mutating or deleting the NLSs-coding N-terminal region of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1).
  • nucleic acid molecules encoding a cytoplasmic TIF2 polypeptide will be fragments having a deletion in all or part of the N-terminal NLSs coding region.
  • the cytoplasmic TIF2 polypeptides described herein display at least one biological activity that is substantially similar to at least one biological activity of TIF2.
  • nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98%, or 99% identical to the above described nucleic acid molecules.
  • the present invention also relates to vectors which contain the above-described isolated nucleic acid molecules, host cells transformed with the vectors and the production of TIF2 polypeptides by recombinant methods.
  • the present invention further provides isolated TIF2 polypeptides having the amino acid sequence shown in Figure 1 (SEQ ID NO:2).
  • isolated TIF polypeptides are provided having an amino acid sequence as encoded by the cDNA deposited as ATCC Deposit No. 97612.
  • Screening methods are also provided for identifying agonists and antagonists of nuclear receptor AF-2 function, for identifying agonists and antagonists of TIF2 AD1 activity, and for identifying agonists and antagonists of TIF2 AD2 activity. Also provided are TIF2 antibodies.
  • the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding transcriptional intermediary factor-2 (TIF2) whose amino acid sequence is shown in Figure 1 (SEQ ID NO:2).
  • TIF2 protein of the present invention shares sequence homology with the human steroid receptor coactivator SRC-1 (SEQ ID NO:3) ( Figure 3).
  • SRC-1 human steroid receptor coactivator SRC-1
  • Figure I The nucleotide sequence shown in Figure I (SEQ ID NO:1) was obtained by sequencing a cDNA clone which was deposited on June 14, 1996 at the ATCC and given accession number 97612.
  • isolated nucleic acid molecules are provided which encode the TIF2 protein. Sequence similarities between TIF2 and SRC-1 ( Onate et al., Science 270:1354 (1995 )) indicate the existence of a novel gene family of NR transcriptional mediators. Using information provided herein, such as the nucleotide sequence in Figure 1 (SEQ ID NO:1) or the above-described deposited clone, a nucleic acid molecule of the present invention encoding a TIF2 polypeptide may be obtained using standard cloning and screening procedures. Illustrative of the invention, the nucleic acid molecule described in Figure 1 (SEQ ID NO:1) was discovered in a cDNA expression library from human placenta tissue.
  • the TIF2 cDNA of the present invention encodes a protein of about 159 kDa (1,464 amino acids), which includes N-terminal nuclear localization signals (NLSs), one Gln- and three Ser/Thr-rich regions, and two charged clusters (Figure 3). TIF2 is widely expressed, since the corresponding transcript was found in several human tissues, including pancreas, kidney, muscle, liver, lung, placenta, brain and heart (Figure 2c).
  • Isolated nucleic acids of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically.
  • the DNA may be double-stranded or single-stranded.
  • Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.
  • isolated nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment.
  • recombinant DNA molecules contained in a vector are considered isolated for purposes of the present invention.
  • Additional illustrative examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells and purified (partially or substantially) DNA molecules in solution.
  • Isolated RNA molecules include in vitro RNA transcripts of the DNA molecules of the present invention as well as partially or substantially purified mRNA molecules. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.
  • Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) with an initiation codon at position 163-165 of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1); and DNA molecules which comprise a sequence substantially different than that described above but which, due to the degeneracy of the genetic code, still encode the TIF2 protein.
  • ORF open reading frame
  • SEQ ID NO:1 DNA molecules which comprise a sequence substantially different than that described above but which, due to the degeneracy of the genetic code, still encode the TIF2 protein.
  • the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate variants described above.
  • the invention provides isolated nucleic acid molecules encoding the TIF2 polypeptide having an amino acid sequence as encoded by the cDNA clone deposited as ATCC Deposit No. 97612 on June 14, 1996 (American Type Culture Collection, (ATCC) Rockville, MD).
  • the invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) or the nucleotide sequence of the TIF2 cDNA contained in the above-described clone, or a nucleic acid molecule having a sequence complementary to one of the above sequences.
  • Such isolated nucleic acid molecules preferably DNA molecules, are useful as probes for gene mapping by in situ hybridization with chromosomes and for detecting expression of the TIF2 gene in human tissue, for instance, by Northern blot analysis.
  • the invention provides an isolated nucleic acid molecule that hybridizes under stringent conditions to the above-described nucleic acid molecules.
  • stringent conditions is intended to mean, as a nonlimiting example, overnight incubation at 42°C in a solution comprising 50% formamide, 5xSSC (150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1xSSC at about 65°C.
  • such "an isolated nucleic acid molecule that hybridizes under stringent conditions” will be at least 15 bp, preferably at least 20 bp, more preferably at least 30 bp, and most preferably, at least 50 bp in length.
  • fragments of an isolated DNA molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in Figure 1 is intended to mean DNA fragments at least 15 bp, more preferably at least 20 bp, and most more preferably at least 30 bp in length which are useful as diagnostic probes and primers as discussed above and in more detail below. Larger DNA fragments, up to, for example, 500 bp in length, are also useful as probes according to the present invention.
  • a fragment of at least 20 bp in length is intended to mean fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1). As indicated, such fragments are useful diagnostically either as a probe according to conventional DNA hybridization techniques or as primers for amplification of a target sequence by the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • DNA fragments of the present invention can be generated synthetically according to the methods and techniques known and available to those skilled in the art.
  • TIF-2 nucleoide sequence Ten expressed sequence tags with homology to part of the TIF-2 nucleoide sequence were identified by the inventors in GenBank: GenBank Accession numbers T77249, R77864, T77464, R77770, R08880, T85560, R25318, T85561, R08986 and R26517.
  • the present invention further relates to variants of the nucleic acid molecules of the present invention, which encode for fragments, analogs or derivatives of the TIF2 protein, e . g ., polypeptides having biological activity substantially similar to the TIF2 protein.
  • Variants may occur naturally, such as isoforms and allelic variants.
  • Non-naturally occurring variants may be produced using any of the mutagenesis techniques known and available to those skilled in the art.
  • variants include those produced by nucleotide substitutions, deletions or additions.
  • the substitutions, deletions or additions may involve one or more nucleotides.
  • the variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the TIF2 protein or fragment thereof. Also especially preferred in this regard are conservative substitutions.
  • the present invention is further directed to isolated nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide.
  • Full-length TIF2 is a nuclear protein due to the presence of N-terminal nuclear localization signals (NLSs) ( Figure 3).
  • NLSs nuclear localization signals
  • cytoplasmic TIF2 polypeptide is intended a TIF2 polypeptide that is essentially found in the cytoplasm after being recombinantly expressed in mammalian cells.
  • Methods for generating nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide include mutating or deleting the NLSs-coding N-terminal region of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1).
  • NLS sequences include amino acids 13-20 and 31-39 and nucleotides 199-222 and 253-279 of Figure 1 ( See also, Figure 3).
  • Suitable mutations to the NLSs-coding N-terminal region include substitutions, deletions and insertions which result in a nucleic acid molecule that encodes a TIF2 polypeptide lacking the nuclear localization function. Methods for generating such mutations will be readily apparent to the skilled artisan and are described, for instance, in Molecular Cloning, A Laboratory Manual, 2nd edition, edited by Sambrook, J., Fritsch, E.F. and Maniatis, T., (1989), Cold Spring Harbor Laboratory Press .
  • nucleic acid molecules encoding a cytoplasmic TIF2 polypeptide will be fragments having a deletion in all or part of the N-terminal NLSs coding region. Methods for generating such fragments are described below. According to the present invention, such nucleic acid fragments further include N-terminal deletions extending beyond the NLSs coding region and may also include C-terminal deletions.
  • the present inventors have generated a nucleic acid molecule encoding the cytoplasmic TIF2.1 polypeptide (amino acids 624 to 1287 in Figures 1 and 3 (SEQ ID NO: 2)), which, like the nuclear full-length TIF2, interacts in an agonist-dependent manner with the nuclear receptors and enhances nuclear receptor-mediated transcriptional activation.
  • the present inventors have also generated a nucleic acid molecule encoding the cytoplasmic TIF2.5 polypeptide (amino acids 624-869 in Figures 1 and 3 (SEQ ID NO:2)), which interacts with the NID domain of nuclear receptors, but does not enhance transcription.
  • nucleic acids encoding the cytoplasmic TIF2.8 and TIP 2.12 polypeptides (amino acids 1010-1179 and amino acids 940-1131, respectively, in Figures 1 and 3 (SEQ ID NO:2), which enhance transcription, but do not bind to nuclear receptors.
  • nucleic acid molecules are provided encoding cytoplasmic TIF2 polypeptides that interact in an agonist-dependent manner with nuclear receptors and enhance nuclear receptor-mediated transcriptional activation.
  • cytoplasmic TIF2 polypeptides that bind to nuclear receptors, but do not enhance transcription as are provided cytoplasmic TIF2 polypeptides that enhance transcription, but do not bind to nuclear receptors.
  • the length of such nucleic acid molecules can vary.
  • nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98%, or 99% identical to: (a) the nucleotide sequence of the cDNA deposited as ATCC 97612; (b) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1); (c) the nucleotide sequence of the cDNA deposited as ATCC 97612 which encodes the full-length TIF2 protein; (d) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), which encodes the full-length TIF2 protein; (e) the nucleotide sequence of the cDNA deposited as ATCC 97612, which encodes the functional coactivator TIF2.1 protein; (f) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), which encodes the functional coactivator TIF2.1 protein; (g) the nucleotide sequence shown in Figure
  • nucleic acid molecules have nucleotide sequences that are at least 90%, 95%, 96%, 97%, 98%, or 99% “identical” can be determined conventionally using known computer algorithms such as the "fastA” program using, for example, the default parameters ( Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988 )).
  • the present application is directed to such nucleic acid molecules having a nucleotide sequence at least 90%, 95%, 96%, 97%, 98%, 99%, identical to the nucleotide sequence of the above-recited nucleic acid molecules irrespective of whether they encode a polypeptide having TIF2 activity.
  • nucleic acid molecules of the present invention that do not encode a polypeptide having TIF2 activity include, inter alia , (1) isolating the TIF2 gene or allelic variants thereof in a cDNA library; (2) in situ hybridization (FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the TIF2 gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988 ); and Northern Blot analysis for detecting TIF2 mRNA expression in specific tissues, such as placenta tissue.
  • FISH in situ hybridization
  • a polypeptide having a TIF2 protein activity is intended to mean polypeptides exhibiting similar, but not necessarily identical, activity as at least one biological activity of the TIF2 protein as measured in a particular biological assay.
  • the TIF2 protein of the present invention interacts directly in an agonist-dependent manner with the ligand binding domains of several nuclear receptors.
  • the TIF2 protein of the present invention enhances transcription via CBP-dependent and' CBP-independent routes.
  • a polypeptide having a TIF2 protein activity includes polypeptides having one or more of the following activities: interaction with the LBD of one or more NRs in an agonist-dependent manner; enhancement of CBP-dependent transcriptional activation; or enhancement of CBP-independent transcriptional activation.
  • TIF2.2 is "a polypeptide having a TIF2 protein activity.
  • TIF 2.8 is a "polypeptide having a TTF2 protein activity” as it activates CBP-dependent transcription.
  • nucleic acid molecules having a nucleotide sequence at least 90%, preferably at least 95%, 96%, 97%, 98%, 99% identical to the nucleotide sequence of the above-described nucleic acid molecules will encode "a polypeptide having a TIF2 protein activity.”
  • degenerate variants all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described screening assays.
  • a reasonable number will also encode a polypeptide having a TIF2 protein activity. This is because the skilled artisan is fully aware of possible amino acid substitutions that are either less likely or not likely to significantly affect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).
  • the present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of TIF2 polypeptides or fragments thereof, such as TIF2.1, by recombinant techniques.
  • Recombinant constructs may be introduced into host cells using well known techniques such infection, transduction, transfection, transvection, electroporation and transformation.
  • the vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.
  • the polynucleotides may be joined to a vector containing a selectable marker for propagation in a host.
  • a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.
  • vectors comprising cis-acting control regions to the polynucleotide of interest.
  • Appropriate trans-acting factors may be supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.
  • the vectors provide for specific expression, which may be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.
  • Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.
  • vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses and vectors derived from combinations thereof, such as cosmids and phagemids.
  • the DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few.
  • an appropriate promoter such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few.
  • Other suitable promoters will be known to the skilled artisan.
  • the expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation.
  • the coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating AUG at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.
  • the expression vectors will preferably include at least one selectable marker.
  • markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in E. coli and other bacteria.
  • Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, Cos and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.
  • vectors preferred for use in bacteria include, but are not limited to, pA2, pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia.
  • Preferred eukaryotic vectors include, but are not limited to, pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.
  • bacterial promoters suitable for use in the present invention include the E. coli lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters and the trp promoter.
  • Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV”), and metallothionein promoters, such as the mouse metallothionein-I promoter.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986 ).
  • Enhancers are cis-acting elements of DNA, generally about 10 to 300 bp in size, that act to increase transcriptional activity of a promoter in a given host cell-type.
  • Illustrative examples of enhancers include, but are not limited to, the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • secretion signals may be incorporated into the expressed polypeptide.
  • the signals may be endogenous to the polypeptide or they may be heterologous signals.
  • the polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions.
  • a region of additional amino acids, particularly charged amino acids may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage.
  • peptide moieties may be added to the polypeptide to facilitate purification.
  • the TIF2 protein or fraction thereof can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification.
  • HPLC high performance liquid chromatography
  • Polypeptides of the present invention include, but are not limited to, naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells.
  • a prokaryotic or eukaryotic host including, for example, bacterial, yeast, higher plant, insect and mammalian cells.
  • the polypeptides of the present invention may be post translationally modified (e.g., glycosylated, phosphorylated, farnesylated, etc.).
  • polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.
  • the invention further provides an isolated TIF2 polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence as shown in Figure 1 (SEQ ID NO:2), or a fragment thereof.
  • Preferred polypeptide fragments will have a TIF2 protein activity.
  • TIF2 polypeptide fragments should at least include amino acid residues 624 to 1131 as shown in Figure 1(SEQ ID NO:2) or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to interact in an agonist-dependent manner with nuclear receptors and to enhance nuclear receptor-mediated transcriptional activation.
  • the TIF2 polypeptide fragments should at least include amino acids 624-869 as shown in Figure 1 (SEQ ID NO:2), or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to interact with the LBD of an NR.
  • the TIF2 polypeptide should at least include amino acid residues 1010-1131 as shown in Figure 1 (SEQ ID NO:2) or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to activate CBP-dependent transcription.
  • the TIF2 polypeptide should at least include amino acid residues 1288-1464 as shown in Figure 1 (SEQ ID NO:2) or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to activate CBP-indepentent transcription.
  • Exemplary TIF2 polypeptide fragments according to the present invention include cytoplasmic TIF2 polypeptides having at least one mutation or deletion in a N-terminal NLS region that interferes with the nuclear localization function. Methods for generating cytoplasmic TIF2 polypeptides are described above.
  • an "isolated" polypeptide or protein is intended to mean a polypeptide or protein removed from its native environment, such as recombinantly produced polypeptides and proteins expressed in host cells and native or recombinant polypeptides which have been substantially purified by any suitable technique (e . g ., the single-step purification method disclosed in Smith and Johnson, Gene 67:31-40 (1988 ), which is incorporated by reference herein). Isolated polypeptides or proteins according to the present invention further include such compounds produced synthetically.
  • the full-length TIF2 protein is an about 1464 amino acid residue protein with a deduced molecular weight of about 160 kDa. It will be recognized by those skilled in the art that some amino acid sequence of the TIF2 protein can be varied without significant effect on the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity, such as the region described above which has been determined by the inventors as being critical to the protein's ability to enhance nuclear receptor-mediated transcriptional activation. In general, it is often possible to replace residues which form the tertiary structure, provided that residues performing a similar function are used. In other instances, the type of residue may be completely unimportant if the alteration occurs at a non-critical region of the protein.
  • the present invention further includes variations of the TIF2 polypeptide which show substantial TIF2 polypeptide activity or which include regions of TIF2 protein such as the protein fragments discussed below.
  • Such mutants include deletions, insertions, inversions, repeats, and type substitutions (for example, substituting one hydrophilic residue for another, but not strongly hydrophilic for strongly hydrophobic as a rule). Small changes or such "neutral" amino acid substitutions will generally have little effect on activity.
  • conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.
  • polypeptides of the present invention include polypeptides having an amino acid sequence as encoded by the deposited cDNA, an amino acid sequence as shown in SEQ ID NO:2, as well as an amino acid sequence at least 80% identical, more preferably at least 90% identical, and most preferably at least 95%, 96%, 97%, 98%, or 99% identical, to the amino acid sequence encoded by the deposited cDNA, to the amino acid sequence as shown in SEQ ID NO:2, or to the amino acid sequence of a polypeptide fragment described above. Whether two polypeptides have an amino acid sequence that is at least 80%, 90% or 95% identical can be determined using a computer algorithm as described above.
  • nucleic acid molecules and polypeptides of the present invention are useful in screening assays for identifying agonist and antagonist of NR AF2-mediated transactivation.
  • NR AF2-mediated transactivation For example, in Halachmi, S., et al., Science 264: 1455 (1994 ), the authors show that tamoxifen, which has growth inhibitory effects in breast cancer, disrupts the formation of a complex that includes the estrogen receptor and ERAP160.
  • the nucleic acid molecules and polypeptides of the present invention are useful in assays for identifying drugs capable of enhancing or inhibiting nuclear receptor-mediated pathways.
  • nucleic acid molecules and polypeptides of the present invention are useful in screening assays for identifying agonists and antagonists of TIF2 AD1 activity, and in screening assays for identifying agonist and antagonists of TIF2 AD2 activity, as described in detail below.
  • Nuclear receptors are members of a superfamily of ligand-inducible transcriptional regulatory factors that include steroid hormone, thyroid hormone, vitamin D3 and retinoid receptors ( Leid, M., et al., Trends Biochem. Sci. 17:427-433 (1992 ); Leid, M., et al., Cell 68:377-395 (1992 ); and Linney, E. Curr. Top. Dev. Biol., 27:309-350 (1992 )). NRs exhibit a modular structure which reflects the existence of several autonomous functional domains.
  • Region E is functionally complex, since in addition to the ligand-binding domain (LBD), it contains a ligand-dependent activation function (AF-2) and a dimerization interface.
  • An autonomous transcriptional activation function (AF-1) is present in the non-conserved N-terminal A/B regions of the steroid receptors.
  • AF-1 and AF-2 of steroid receptors exhibit differential transcriptional activation properties which appear to be both cell type and promoter context specific ( Gronemeyer, H. Annu. Rev. Genet. 25:89-123 (1991 )).
  • the all- trans (T-RA) and 9- cis (9C-RA) retinoic acid signals are transduced by two families of nuclear receptors, RAR ⁇ , ⁇ and ⁇ (and their isoforms) are activated by both T-RA and 9C-RA, whereas RXR ⁇ , ⁇ and ⁇ are exclusively activated by 9C-RA ( Allenby, G. et al., Proc. Natl. Acad. Sci. USA 90:30-34 (1993 )).
  • the three RAR types differ in their B regions, and their main isoforms ( ⁇ 1 and ⁇ 2, ⁇ 1-4, and ⁇ 1 and ⁇ 2) have different N-terminal A regions ( Leid, M. et al., Trends Biochem. Sci. 17:427-433 (1992 )).
  • the RXR types differ in their A/B regions ( Mangelsdorf, D.J. et al, Genes Dev. 6:329-344 (1992 )).
  • RAR/RXR heterodimers bind much more efficiently in vitro than homodimers of either receptor to a number of RA response elements (RAREs) ( Yu, V.C. et al., Cell 67:1251-1266 (1991 ); Berrodin, T. J. et al., Mol. Endocrinol 6:1468-1478 (1992 ); Bugge, T. H. et al., EMBO J.
  • RAR and RXR heterodimers are also preferentially formed in solution in vitro ( Yu, V. C. et al., Cell 67:1251-1266 (1991 ); Leid, M. et al., Cell 68:377-395 (1992 ); Marks, M. S. et al., EMBO J. 11:1419-1435 (1992 )), although the addition of 9C-RA appears to enhance the formation of RXR homodimers in vitro ( Lehman, J. M. et al., Science 258:1944-1946 (1992 ); Zhang, X. K.
  • retinoids are used in a variety of chemopreventive and chemotherapeutic settings.
  • the prevention of oral, skin and head and neck cancers in patients at risk for these tumors has been reported ( Hong , W. K. et al., N. Engl. J. Med. 315:1502-1505 (1986 ); Hong, W. K.
  • the present inventors have cloned a gene encoding TIF2 and have shown that TIF2 and a cytoplasmic fragment thereof bind, in an agonist-dependent manner, to all nuclear receptors analyzed- RAR, RXR, ER, TR, VDR, GR and AR. Further, the present inventors have shown that TIF2 polypeptides are transcriptional mediators of the nuclear receptor AF-2.
  • the present invention further provides a screening method for identifying a nuclear receptor (NR) antagonist, which involves: (a) providing a host cell containing recombinant genes which express a polypeptide comprising a NR ligand binding domain (LBD) and a polypeptide comprising transcriptional intermediary factor-2 (TIF-2) or a TIF-2-fragment, wherein, in the presence of an agonist, said TIF-2 and said TIF-2-fragment bind said NR LBD; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist reduces either: (1) TIF-2- or TIF-2-fragment-binding to the AF-2 of said NR LBD as compared to said binding in the absence of said candidate antagonist; or (2) TIF-2- or TIF-2-fragment-stimulated NR LBD AF-2-mediated transactivation as compared to said transactivation in the absence of said candidate antagonist.
  • NR nuclear receptor
  • a screening method for identifying a nuclear receptor (NR) agonist, which involves: (a) providing a host cell containing recombinant genes which express a polypeptide comprising a NR ligand binding domain (LBD) and a polypeptide comprising transcriptional intermediary factor-2 (TIF-2) or a TIF-2-fragment, wherein, in the presence of an agonist, said TIF-2 and said TIF-2-fragment bind said NR LBD; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances either: (1) TIF-2- or TIF-2-fragment-binding to the AF-2 of said NR LBD as compared to said binding in the absence of said candidate agonist; or (2) TIF-2- or TIF-2-fragment-stimulated NR LBD AF-2-mediated transactivation as compared to said transactivation in the absence of said candidate agonist.
  • LBD NR ligand binding domain
  • TIF-2 transcriptional intermediary
  • a host cell containing recombinant genes is intended host cells-into which one or more of the recombinant constructs described herein have been introduced or a progeny of such host cells.
  • Candidate antagonist and agonist according to the present invention include 'dissociating' ligands for nuclear receptors such as those described in Chen et al., EMBO J. 14:1187-1197 (1995 ) and Ostrowski et al., Proc. Natl. Acad. Sci. USA 92:1812-1816 (1995 ). Progesterone and glucocorticoid receptor agonist and antagonist are described in Meyer et al., EMBO J. 9 (12): 3923-3932 (1990) . An estrogen receptor antagonist is described in Halachmi et al., Science 264: 1455-1458 (1994 ). Thus, methods are known in the art for developing candidate nuclear receptor agonist and antagonist for screening according to the present invention.
  • the crystal structure of the ligand binding domains of certain nuclear receptors have been described.
  • the crystal structure of the RXR LBD is described in Bourguet et al., Nature 375:377-382 (1995 ); the crystal structure of the RAR LBD is described in Renaud et al., Nature 378:681-689 (1995 ); and the crystal structure of a thyroid hormone receptor is described in Wagner et al., Nature 378:690-697 (1995 ).
  • computer programs are available for designing the structure of candidate agonist and antagonist which would likely bind to the ligand binding domain. Suitable computer program packages for this purpose include WHAT IF ( Vriend, G., J Mol. Graphics 8:52-56 (1990 )), and GRID ( Goodford, J. Med. Chem. 28:849-857 (1985 )).
  • Recombinant genes encoding a polypeptide comprising TIF2 or a TIF2-fragment capable of binding nuclear receptors in an agonist -dependent manner are described above.
  • Recombinant genes encoding a polypeptide comprising a NR LBD have been described in great detail in the art. Methods for determining whether a candidate agonist or antagonist enhances or interferes with TIF-2 or TIF-2-fragment binding to a NR are known in the art.
  • the effect of a candidate agonist or antagonist on TIF2- or TIF-2-fragment-binding to a NR LBD can be studied using glutathione-S-transferase (GST) interaction assays by tagging NR LBDs with GST as described in detail in the Experimental section below and in Le Douarin et al., EMBO J 14:2020-2033 (1995 ).
  • GST glutathione-S-transferase
  • the recombinant genes will encode a chimeric polypeptide comprising a NR LBD fused to a DNA binding domain from a transactivator protein.
  • the host cell expressing the recombinant genes will also express a reporter gene. For example, in Chen et al., EMBO J. 14(6):1187-1197 (1995 ), three 'reporter' cell lines have been established in which RAR ⁇ , RAR ⁇ , or RAR ⁇ agonists induce luciferase activity that can be measured in the intact cells using a single-photon-counting camera.
  • the ER expression vectors HEO, HE19 and HE15, the GR expression vectors HG1 and HG3 and the PR expression cPR1 and cPR3 are described in Kumar et al., Cell 51:941-951 (1987 ) and Gronemeyer et al., EMBO J. 6:3985-3994 (1987 ).
  • the GR expression vector HG8 and the PR expression vector cPR5A are described in Bocquel et al., Nucl. Acids Res. 17:2581-2595 (1989 ).
  • Reporter genes for the above described ER, GR and PR expression vectors include MMTV-CAT (in the case and GR; Cato et al., EMBO J. 5:2237-2240 (1986 )) and vit-tk-CAT (in the case of ER; Klein-Hitpass et al., Cell 41:1055-1061 (1986 )).
  • TR expression vector LexA-TR is described in Lee et al., Nature 374:91-94(1995 ), which also describes using the yeast two hybrid system to identify compounds that affect TR transactivation.
  • Still further references disclosing reporter plasmids containing a reporter gene and expression vectors encoding a NR LBD include Meyer et al., Cell 57:433-442 (1989 ); Meyer et al., EMBO J. 9(12):3923-3932 (1990 ); Tasset et al., Cell 62:1177-1187 (1990 ); Gronemeyer, H. and Laudet, V., Protein Profile 2:1173-1308 (1995 ); Webster et al., Cell 54:199-207 (1988 ); Strumblele et al., EMBO J. 7:3389-3395 (1988 ); Seipel et al., EMBO J.
  • the effect of a candidate agonist or antagonist on NR AF-2-mediated transactivation is assayed according to the method described in the legend to Figure 5 above.
  • the present inventors have identified an activation domain of TIF2, AD1 (amino acids 1010-1131 as shown in Figure 1 (SEQ ID NO:2)), which mediates the CBP-dependent transcriptional activation function of TIF2. Further, the present inventors have shown that polypeptides containing this activation domain, when fused to a DNA-binding domain of a transcriptional activator, is capable of activating transcription via a CBP-dependent pathway.
  • the present invention further provides a screening method of identifying an agonist of TIF2 AD1 activation domain activity, which involves: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD1 activation domain 1; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances TIF2 AD1 activation domain activity.
  • DBD transcriptional activator DNA-binding domain
  • the invention further provides for a screening method for identifying an antagonist of TIF2 AD1 activation domain activity, which comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD1 activation domain 1; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist inhibits TIF2 AD1 activation domain activity.
  • a screening method for identifying an antagonist of TIF2 AD1 activation domain activity comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD1 activation domain 1; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist inhibits TIF2 AD1 activation domain activity.
  • DBD transcriptional activator DNA-binding domain
  • transcriptional activator molecules that enhance the initiation of transcription by RNA polymerase B (II).
  • Transcriptional activators include yeast transcriptional activators, such as GAL4 and GCN4; the herpes simplex activator, VP16; and members of the nuclear receptor family, which includes RAR RXR, ER, TR, VDR GR, and AR.
  • Recombinant genes encoding a polypeptide comprising a TIF2 AD1 activation domain are described below.
  • Recombinant genes encoding a polypeptide comprising a transcriptional activator DBD are well known in the art.
  • Methods for determining whether a candidate agonist or antagonist enhances or interferes with transcription are well known in the art.
  • the effect of a candidate agonist or antagonist of TIF2 AD1 activation domain activity can be determined using CAT assays as described below and in Gronemeyer et al. (1987) and Bocquel et al., Nucl. Acids Res. (1989 ).
  • recombinant genes will encode a chimeric polypeptide comprising a transcriptional activator DBD fused to a TIF2 polypeptide comprising the AD1 activation domain.
  • the host cell expressing the recombinant genes will also express a reporter gene. Examples of reporter genes are described above.
  • the effect of a candidate agonist or antagonist of TIF2 AD 1 activation domain function will be determined as described in the legend to Figure 7(c).
  • the present inventors have also identified a second activation domain of TIF2, AD2 (amino acids 1288-1464 as shown in Figure 1 (SEQ ID NO:2)), which mediates CBP-independent transcriptional activation. Further, the present inventors have shown that polypeptides containing this activation domain, when fused to a DNA-binding domain of a transcriptional activator, are capable of activating transcription via a CBP-independent pathway.
  • the present invention further provides a screening method for identifying an agonist of TIF2 AD2 activation domain activity, which comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD2 activation domain; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances TIF2 AD2 activation domain activity.
  • a screening method for identifying an agonist of TIF2 AD2 activation domain activity comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD2 activation domain; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances TIF2 AD2 activation domain activity.
  • DBD transcriptional activator DNA-binding domain
  • the invention further provides for a screening method for identifying an antagonist of TIF2 AD2 activation domain activity, which comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD2 activation domain; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist inhibits TIF2 AD2 activation domain activity.
  • a screening method for identifying an antagonist of TIF2 AD2 activation domain activity comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD2 activation domain; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist inhibits TIF2 AD2 activation domain activity.
  • DBD transcriptional activator DNA-binding domain
  • Recombinant genes encoding a polypeptide comprising a TIF2 AD2 activation domain are described below.
  • Recombinant genes encoding a polypeptide comprising a transcriptional activator DBD are well known in the art.
  • Methods for determining whether a candidate agonist or antagonist enhances or interferes with transcription are known in the art.
  • recombinant genes will encode a chimeric polypeptide comprising a transcriptional activator DBD fused to a TIF2 polypeptide comprising the AD2 activation domain. Transcriptional activators are described above.
  • the host cell expressing the recombinant genes will also express a reporter gene. Examples of reporter genes are described above.
  • the effect of a candidate agonist or antagonist of TIF2 AD2 activation domain activity will be determined as described in the legend to Figure 7(c).
  • TIF2 antibodies are also provided by the present invention, as specific for a TIF2 protein, a TIF2 polypeptide, a TIF2 protein fragment or a TIP2 polypeptide fragment.
  • antibody is meant to include polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, as well as fragments thereof provided by any known technique, such as, but not limited to enzymatic cleavage, peptide synthesis or recombinant techniques.
  • Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen.
  • a monoclonal antibody contains a substantially homogeneous population of antibodies specific to antigens, which population contains substantially similar epitope binding sites.
  • MAbs may be obtained by methods known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497 (1975) ; U.S. Patent No. 4,376,110 ; Ausubel et al, eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Assoc.
  • Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof.
  • a hybridoma producing a mAb of the present invention may be cultivated in vitro, in situ or in vivo . Production of high titers of mAbs in vivo or in situ makes this the presently preferred method of production.
  • Chimeric antibodies are molecules different portions of which are derived from different animal species, such as those having variable region derived from a murine mAb and a human immunoglobulin constant region, which are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine mAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric mAbs are used.
  • Chimeric antibodies and methods for their production are known in the art ( Cabilly et al., Proc. Natl. Acad. Sci.
  • An anti-idiotypic (anti-Id) antibody is an antibody which recognizes unique determinants generally associated with the antigen-binding site of an antibody.
  • An Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the mAb with the mAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody). See, for example, U.S. patent No. 4,699,880 , which is herein entirely incorporated by reference.
  • the anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody.
  • the anti-anti-Id may be epitopically identical to the original mAb which induced the anti-Id.
  • the anti-Id mAbs thus have their own idiotypic epitopes, or "idiotopes" structurally similar to the epitope being evaluated, such as GRB protein- ⁇ .
  • antibody is also meant to include both intact immunoglobulin molecules as well as fragments thereof, such as, for example, Fab and F(ab') 2 , which are capable of binding antigen.
  • Fab and F(ab') 2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody ( Wahl et al., J. Nucl. Med. 24:316-325 (1983) ). It will be appreciated that Fab and F(ab') 2 and other fragments of the antibodies useful in the present invention may be used for the detection and quantitation of a TIF2 according to the methods disclosed herein for intact antibody molecules.
  • Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab') 2 fragments).
  • an antibody is said to be “capable of binding” a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody.
  • epitope is meant to refer to that portion of any molecule capable of being bound by an antibody which can also be recognized by that antibody.
  • Epitopes or "antigenic determinants” usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics.
  • an "antigen” is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen.
  • An antigen may have one, or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.
  • the antibodies, or fragments of antibodies, useful in the present invention may be used to quantitatively or qualitatively detect a TIF2 protein, polypeptide, or fragment, in a sample or to detect presence of cells which express a TIF2 of the present invention. This can be accomplished by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorometric detection.
  • the antibodies (of fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of a TIF2 protein, polypeptide, or fragment, of the present invention.
  • In situ detection may be accomplished by removing a histological specimen form a patient, and providing a labeled antibody of the present invention to such a specimen.
  • the antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample.
  • Such assays for a TIF2 protein, polypeptide, or fragment, of the present invention typically comprises incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells such as lymphocytes or leukocytes, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of identifying a TIF2 protein, polypeptide, or fragment, and detecting the antibody by any of a number of techniques well-known in the art.
  • the biological sample may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins.
  • a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins.
  • the support or carrier may then be washed with suitable buffers followed by treatment with a detectably labeled TIF2-specific antibody.
  • the solid phase support or carrier may then be washed with the buffer a second time to remove unbound antibody.
  • the amount of bound label on said solid support or carrier may then be detected by conventional means.
  • solid phase support By “solid phase support”, “solid phase carrier”, “solid support”, “solid carrier”, “support” or “carrier” is intended any support or carrier capable of binding antigen or antibodies.
  • supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.
  • the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
  • the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody.
  • the support or carrier configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
  • the surface may be flat such as a sheet, test strip, etc.
  • Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.
  • the binding activity of a given lot of anti-TIF2 antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation. Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.
  • TIF2-specific antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA).
  • EIA enzyme immunoassay
  • This enzyme when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means.
  • Enzymes which can be used detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6- phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
  • the detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
  • Detection may be accomplished using any of a variety of other immunoassays.
  • a radioimmunoassay RIA
  • the radioactive isotope can be detected by such means as the use of a ⁇ counter or a scintillation counter or by autoradiography.
  • an anti-TIF2 antibody with a fluorescent compound.
  • fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • the antibody can also be detectably labeled using fluorescence emitting metals such as 152 EU, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (EDTA).
  • fluorescence emitting metals such as 152 EU, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (EDTA).
  • the antibody also can be detectably labeled by coupling it to a chemiluminescent compound.
  • the presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
  • Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
  • An antibody molecule of the present invention may be adapted for utilization in a immunometric assay, also known as a "two-site” or “sandwich” assay.
  • a quantity of unlabeled antibody (or fragment of antibody) is bound to a solid support or carrier and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.
  • Typical, and preferred, immunometric assays include "forward" assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the antigen form the sample by formation of a binary solid phase antibody-antigen complex. After a suitable incubation period, the solid support or carrier is washed to remove the residue of the fluid sample, including unreacted antigen, if any, and then contacted with the solution containing an unknown quantity of labeled antibody (which functions as a "reporter molecule"). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support or carrier through the unlabeled antibody, the solid support or carrier is washed a second time to remove the unreacted labeled antibody.
  • a simultaneous assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support or carrier is then determined as it would be in a conventional "forward" sandwich assay.
  • stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the "simultaneous" and "forward" assays.
  • TIF2.1 protein fragment
  • Human TIF2 cDNA encodes a 159,160 Da protein (1,464 amino acids), which includes N-terminal putative nuclear localization signals (NLSs), one Gln- and three Ser/Thr-rich regions, and two charged clusters (FIG. 3).
  • NLSs N-terminal putative nuclear localization signals
  • SRC-1 steroid receptor coactivator SRC-1
  • TIF2 is the 160-kDa protein species which interacts in an agonist-dependent manner with NR LBDs (see above and Halachmi, S. et al., Science 264:1455-1458 (1994 ); Cavaillies, V. et al., Proc. Natl. Acad. Sci. USA 91:10009-10013 (1994 ); and Kurokawa, R. et al, Nature 377:451-454 (1995 )).
  • Western blotting with a rabbit antiserum (p ⁇ -TIF2) raised against bacterially expressed TIF2.1, revealed predominantly a 160-kDa HeLa cell protein that interacted with agonist-bound GST-ER(DEF) (FIG.
  • TIF2.1 Transiently expressed full-length TIF2 was nuclear and mainly associated with discrete bodies (FIG. 4a). Since the overexpressed TIF2.1 fragment was essentially cytoplasmic (supporting the above assignment of a N-terminal TIF2 NLS), the interaction of TIF2.1 with NRs could be studied in mammalian cells using nuclear cotranslocation assays. In the absence of ligand, TIF2.1 remained cytoplasmic and NRs were nuclear (for RAR ⁇ , ER and PR, see FIGs. 4b, d, g). Agonist exposure, however, resulted in all three cases in nuclear colocalization of TIF2.1 and NR, indicating NR-TIF2 interaction in vivo (FIGs. 4c, e, h).
  • TIF2.1 Agonist-dependent interaction of TIF2.1 with NRs was observed for all other receptors analyzed (RXR, TR, VDR, GR and AR; not shown). Interestingly, no interaction was detected between ER and TIF2.1 in presence of the ER AF-2 antagonist hydroxytamoxifen (OHT) (FIG. 4f), and the PR AF-2 antagonist RU 486 reversed the R5020-induced PR-TIF2.1 interaction (FIG. 4i).
  • OHT hydroxytamoxifen
  • TIF2 In agreement with the Far-Western blot experiments NRs and TIF2 directly interacted, as purified TIF2.1 protein bound in vitro in the presence of an agonist to GST-ER(DEF), GST-RAR ⁇ (DEF), GST-RXR ⁇ (DE) and GST-TR(DE) (FIG. 4k, 1, m, lanes 3 and 4; FIG. 4n, lanes 5 and 6).
  • TIF2 binding to GST-RXR ⁇ (DE) occurred with 9 cis -RA (9C-RA) but not all -trans -RA (T-RA) (FIG. 4n, lanes 1 and 2), and OHT prevented E2-dependent binding of TIF2 to GST-ER(DEF) (FIG. 4n, lanes 7-9).
  • AF-2 AD The integrity of the conserved core of the ER, RAR ⁇ and RXR ⁇ AF-2 activating domains (AF-2 AD) which was shown to be critical for AF-2 activity ( Le Douarin, B. et al., EMBO J. 14:2020-2033 (1995 ); Danielian, P.S. et al., EMBO J. 11:1025-1033 (1992 ); Durand, B. et al., EMBO J. 13:5370-5382 (1994 ); and Gronemeyer, H. and Laudet, V., Protein Profile 2:1173-1308 (1995 ), and therein), was required for TIF2 interaction in vitro. Most AF-2 AD core mutants which have lost AF-2 activity (ER, FIG.
  • TIF2.1 TIF2.1-VP16 (acidic activation domain), GST-TBP, GST-TFIIB, or a series of GST-TAFs (hTAF II 18, hTAF II 20, hTAF II 28 and hTAF II 55; see Jacq, X. et al., Cell 79:107-117 (1994 ); Mengus, G. et al., EMBO J. 14:1520-1531 (1995 )) (not shown).
  • TIF2 may correspond to one of the hypothetical limiting factor(s) previously proposed to be involved in NR transcriptional interference/squelching ( Meyer, M.-E. et al., Cell 57:433-442 (1989 ); Bocquel, M.-T. et al., Nucl. Acids Res. 17:2581-2595 (1989 ); Tasset, D.
  • TIF2.1 coexpression of TIF2.1 with antagonist-bound NR did not lead to any stimulation of the transactivation brought about by AF-1 in the presence of pure AF-2 antagonists ( Berry, M. et al., EMBO J. 9:2811-2818 (1990 ); Meyer, M.E. et al., EMBO J. 9:3923-3932 (1990 )), further supporting that TIF2 is AF-2-specific (FIG. 5b and 5e for ER, OHT; FIG. 5d for PR, RU486).
  • TIF2 expression also increased AF-2/agonist-mediated transactivation by the androgen (AR) and progesterone (PR) receptors, but not transactivation by GAL-VP16 and GAL-AP2 (FIG. 5c).
  • AR androgen
  • PR progesterone
  • GAL-VP16 GAL-VP16
  • GAL-AP2 GAL-AP2
  • transactivation by GAL-RAR, GAL-RXR, GAL-VDR, GAL-TR and GAL-GR were unaffected by TIF2 (FIG. 5c, and not shown), suggesting that for these NRs either TIF2 is not critically involved in mediating their AF-2 activities or endogenous TIF2 amounts are sufficient to optimally support transactivation, for instance, because TIF2 has a higher affinity for these receptors.
  • TIF2-stimulation is to some extent affected by the promoter environment of the responsive gene, as the TIF2 effect on PR/5020-induced transactivation was greater for a complex (MMTV) than for a minimal (GRE-TATA) promoter, although the latter was also reproducibly stimulated (FIG. 5d).
  • MMTV complex
  • GRE-TATA minimal
  • FIG. 5d the effect of TIF2 was cell type-dependent, since TIF2 had a much stronger effect on PR- and ER-induced transactivations in Cos-1 than in HeLa cells (FIGs. 5d, e).
  • mediators should exhibit the following properties: (i) they should bind to agonist-, but not antagonist-bound NR LBDs, (ii) their binding should be prevented by mutations abolishing AF-2 activity, (iii) they should collectively exhibit a transactivation function(s), (iv) their expression should relieve AF-2 autosquelching, and (v) their overexpression should stimulate the activity of AF-2, whenever they are present in limiting amounts.
  • the present study is the first report of a bona fide mediator of NR AF-2s which exhibits all these properties.
  • TIF2 antibodies were made using known techniques, unless otherwise specified below. See, e . g ., Ausubel et al, eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1987-1996 ); Harlow and Lane ANTIBODIES: A LABORATORY MANUAL Cold Spring Harbor Laboratory (1988 ); and Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992-1996 ), the contents of which references are incoporated entirely herein by reference.
  • the TIF2.1 coding sequence (amino acids 624-1287) was cloned into pET15b and the resulting plasmid transformed into the E . coli strain BL21 (DE3). After overexpression of the (His) 6 -TIF2.1 protein the bacteria were lysed and the protein purified from the crude extract via affinity chromatography on a HiTrap chelating column (Pharmacia) as described (see Bourguet et al., Prot. Expr. Purif. 6 :604-608 (1995) for technical details).
  • a 20mer amino-acid peptide of TIF2 (with an added C-terminal cysteine) was selected on the basis of its potential immunogenic characteristics in terms of hydrophilicity, flexibility, surface probability and the 'antigenic index' according to software programmes Plot and Peptidestructure from the GCG package.
  • the chosen peptide corresponds to the N terminal fragment encoded by the TIF2 partial cDNA initially isolated (which encodes amino acids 624 to 1287) and corresponds to amino acids 624 to 643 of the total protein (SEQ ID NO:2):
  • the peptide was coupled to ovalbumin via the additional cysteine using the MBS heterobifunctional crosslinker. Injections were performed in BALB/c mice intraperitonally and intravenously.
  • Spleen cells from the immunized mice were fused to the Sp2/0 Ag14 myeloma.
  • Growing hybridomas were first screened by ELISA using the recombinant TIF2.1 protein and the free peptide. Positive cultures were then tested by immunocytofluorescence on Cos cells transfected with TIF2.1 (in the pSG5 vector) as well as by western blot using the transfected Cos cell extracts and HeLa nuclear extract. The positive cultures were also tested for their ability to immunoprecipitate the TIF2.1 protein from Cos transfected cells.
  • GST-fusions of nuclear receptors were expressed from the following previously described plasmids: GST (pGEX2T; Pharmacia), GST-ER (pGEX2T-hER ⁇ (DEF), also called pGEX2THE14G, amino acids 282-595), GST-RXR (pGEX2T-mRXR ⁇ (DE), amino acids 205-467), and GST-RAR (pGEX2T-hRAR ⁇ (DEF), amino acids 153-462) (all LeDouarin, B. et al., EMBO J. 14:2020-2033 (1995a )).
  • TIF2 NR interaction domain To further delineate the TIF2 NR interaction domain (NID), we studied the interaction between a series of TIF2 deletion mutants and the ER or RAR ⁇ LBDs, using GST-fusion protein-based in vitro assays. In both cases, an NID was mapped to the central region of TIF2 (amino acids 624-869 in mutant TIF2.5; see FIGS. 7a and b). No additional NID could be identified in the N- or C-termini of TIF2 (FIGS. 7a and b; mutants TIF2.0, TIF2.2 and TIF2.7).
  • SRC-1 a paralogue of TIF2
  • SRC-1 a paralogue of TIF2
  • TIF2.5 was C-terminally truncated to Pro775, yielding TIF2.34 which also interacted with ER and RAR ⁇ LBDs in a ligand-dependent manner (FIGS. 8a and c).
  • Ser697 the resulting mutant still interacted with both ER and RAR ⁇ LBDs but, surprisingly, a ligand-dependent interaction was also found with TIF2.36 (FIGS. 8a and c), thus indicating that the TIF2 NID is composed of at least two autonomous NO-interacting modules.
  • TIF2.1 constructs in which two NR box motifs were mutated still exhibited ER binding and stimulation of AF-2 activity, in particular when the NR box motif II was intact, suggesting that the three NR box-containing modules are at least in part, functionally redundant (FIGS. 8d and e; TIF2.1m12, m13, and m23). This redundancy was obvious when only one NR box motif was mutated; in contrast to TIF1 ⁇ , which contains only one NR box ( LeDouarin, B. et al., EMBO J. 15:6701-6715 (1996 )), mutation of a single TIF2 NR box did not abrogate ER binding and stimulation of ER AF-2 activity.
  • TIF2 contains a single nuclear receptor-interaction domain (NID).
  • NID nuclear receptor-interaction domain
  • the TIF-2 NID is composed of three modules, and each can bind independently in a ligand-dependent manner to the NRs tested in this study.
  • these modules contain the NR box motif LxxLL (SEQ ID NO:12), which was originally recorded (as the motif LxxLLL (SEQ ID NO:13), FIG. 8b) within a 10 amino acid NR binding module of TIF1 ⁇ which was found to be conserved in the NID of RIP 140 and also present in TRIP3 ( LeDouarin, B. et al., EMBO J. 15:6701-6715 (1996 ) and refs therein).
  • the TIF1 ⁇ and RIP140 modules were shown to functionally interact with NRs ( LeDouarin, B.
  • mutants with single intact NR boxes were 5 (box II) to 20 (box I or III) times less efficient than the wild-type TIF2 containing the three NR boxes.
  • Crystallography studies will be necessary to distinguish between two possible models, in which the three NR box motifs (i) contribute to the formation of a tripartite NID surface that specifically recognizes a cognate holo-NO LBD surface, or (ii) belongs to independent surfaces which each can interact, albeit with different efficiencies, with the same holo-NO surface.
  • the second model could allow TIF2 to interact cooperatively with both partners of NR homo- or heterodimers, thus rendering transactivation by NRs sensitive to small variations in TIF2 levels.
  • the effects of NR box mutations on NR binding and stimulation of AF-2 activity were correlated, further supporting the conclusion that the transcriptional effect of TIF2 involves the formation of a NR box-NO LBD interaction interface.
  • Transient transfection assays with a GAL4 reporter plasmid and chimeras containing various TIF2 fragments linked to the GAL4 DNA binding domain (DBD) demonstrated the presence of two autonomous transcriptional activation domains in the C-terminal 460 amino acids of TIF2, termed AD1 and AD2 (delineated by mutants TIF2.8, TIF2.12 and TIF2.2 in FIGS. 7a and c).
  • Transient transfections of HeLa and Cos-1 cells were performed as described (Gronemeyer et al ., (1987); Bocquel, M.T. et al., Nucl. Acids Res. 17:2581-2595 (1989 )).
  • the N-terminal AD1 (amino acids 1010-1131), which is present in TIF2.1, showed a stronger activity than the C-terminal AD2 (amino acids 1288-1464) (compare TIF2.8 and TIF2.12 with TIF2.2 in FIGS. 7a and c). Note, however, that the weaker activity of AD2 (relative to AD1) could be due to a lower expression level of the GAL-TIF2.2 fusion protein (compare with GAL-TIF2.8 and GAL-TIF2.12 in FIG. 7c). Both TIF2 activation functions were active in Cos-1 and HeLa cells (FIG. 7c).
  • the minimal AD1 (TIF2.8) and AD2 (TIF2.2) constructs exhibited some cell-specific activities, as GALTIF2.8 was more active in HeLa than in Cos cells, whereas the opposite was observed for GAL-TIF2.2 (FIG. 7c).
  • the glutamine-rich region of TEF2 could neither activate transcription on its own when fused to the GAL4 DBD (FIGS. 7a and c; mutant TIF2.6), nor was it required for transcriptional activation by AD 1 or AD2. No activation function could be detected in the N-terminal part of TIF2 (see FIGS. 7a and c; mutant TIF2.0).
  • NID nuclear receptor interacting domain
  • TIF2 nuclear receptor interacting domain
  • CBP and p300 originally identified as coactivators of the transcription factor CREB, were shown to act as general integrators of multiple signaling pathways, including activation via agonist-bound RAR ⁇ and TR (for reviews and refs see Eckner, R., Biol. Chem. 377:685-688 (1996 ); Janknecht & Hunter,(1996); Glass, C.K. et al., Current Opin. Cell Biol. 9:222-232 (1997 ); Shikama, N. et al., Trends Cell Biol. 7:230-236 (1997 )). Furthermore, it was reported that SRC-1, which belongs to the same gene family as TIF2, interacts with CBP and p300 ( Kamei, Y.
  • FIG. 7a scored positive for interaction with GAL-CBP (containing amino acids 1872-2165 of CBP, which encompass the SRC-1 interacting domain of CBP; FIG. 7e).
  • a GST-CBP fusion protein was expressed in E. coli and used for pull-down assays with in vitro translated TIF2 polypeptides (FIG. 7d).
  • TIF2 did interact with CBP and, interestingly, the CBP-interacting domain (CID) apparently overlapped the AD1 activation domain of TIF2 (compare FIGS. 7a, c and d; mutants TIF2.8 and TIF2.12).
  • the interaction of TIF2 with CBP was direct, as a purified E. coli-expressed TIF2.1 protein also interacted with GST-CBP (data not shown).
  • TIF2 AD1 activity may originate from the recruitment of CBP.
  • Purger N-terminal regions FIGS. 7a and d; mutants TIF2.10 and TIF2.4
  • the C-terminal AD2 activation domain FIGS. 7a and d; mutant TIF2.2
  • TIF2.2 also did not interact win full-length CBP (data not shown), suggesting that the activity of TIF2 AD is mediated by (a) factor(s) distinct from CBP.
  • TIF2.13 which encompasses Pro 1011 to Ser 1122 ) exhibited a potent transcriptional activity, comparable to that of larger TIF2 fragments (compare FIGS. 7 and 9). Removal of 26 C-terminal (TIF2.15) or 20 N-terminal (TIF2.18) amino acid residues reduced transcriptional activity only weakly (FIGS. 9a and b). Note that TIF2.13 also interacted with CBP in vivo , as shown by using a two hybrid assay in transfected mammalian cells (FIG. 10b).
  • the two TIF2 activation functions AD1 and AD2 apparently operate through different transcriptional activation cascades. While the TIF2 AD1 activation domain could not be separated by mutational analysis from the TIF2 domain which interacts in vitro and in vivo with a region of the CBP surface which also mediates SRC-1 binding ( Kamei, Y. et al., Cell 85:403-414 (1996 )), neither this region, nor full length CBP, interacted with TIF2 AD2. That the two TIF2 activation functions may operate through distinct pathways is also suggested by the differential cell specificity of the minimal fragments exhibiting AD1 activity (e.g., TIF2.8, TIF2.7, TIF2.9, TIF2.12) and AD2 activity (TIF2.2).
  • AD1 activity e.g., TIF2.8, TIF2.7, TIF2.9, TIF2.12
  • TIF2.2 is more active in Cos-1 than in HeLa cells
  • all of the minimal fragments containing AD1 are more active in HeLa cells.
  • removal in TIF2.3 of sequences N-terminal of TIF2.8 resulted in a 10-fold and 2-fold increased transactivation in Hela and Cos-1 cells, respectively
  • removal in TIF2.1 of sequences C-terminal ofTIF2.3 gave a 9-fold and 3-fold higher transactivation in Hela and Cos-1 cells, respectively.
  • the deleted sequences could exert either intra- or intermolecular repression on TIF2 AD1 activity/CBP interaction.
  • the coactivator activity of TIF2 may be cell-specifically modulated by the differential efficiency of its two ADs and factors interacting with the sequences N- and C-terminally of the AD1 activation function.
  • AD1 (TIF2.32) on its own is a very poor transactivator and CBP binder, and requires additional surrounding sequences to generate a fully active (i.e., efficient CPB binding) surface.
  • mutational analysis of the AD1 core in the context of a strong activator fragment (TIF2.13) reveals the critical importance for transactivation and CBP binding in vivo and in vitro of three leucine residues (FIG. 10). These leucines belong to a conserved LLxxLxxxL (SEQ ID NO:14) motif in all three members of the TIF2 coactivator family (FIG. 9a; Torchia, J.
  • TIF2 can apparently fulfill at least two mediator functions, (i) as a "bridging factor" between the AF-2 function of nuclear receptors and CBP via its AD1 activation domain and (ii) as a transcriptional mediator through as yet unknown CBP binding-independent route(s) via its AD2 function.
  • a "bridging factor” between the AF-2 function of nuclear receptors and CBP via its AD1 activation domain
  • a transcriptional mediator through as yet unknown CBP binding-independent route(s) via its AD2 function.
  • TIF2 could possess an intrinsic enzymatic activity
  • none of the bacterially-expressed purified TIF2 fragments, in particular TIF2.1 which was shown to be fully competent in NR and CBP interactions in vitro , exhibited any histone acetylase activity under conditions where bacterially-expressed purified yeast GCN5 was highly active (our unpublished results).
  • the hER ⁇ constructs were expressed from the following YEp90-based plasmids: HEGO (hER ⁇ , YEp90-HEG0, amino acids 1-595), HE15 (YEp90-HE15, amino acids 1-282), and HEG19 (YEp90-HEG19, amino acids 179-595) (all Pierrat, B. et al., Gene 119:237-245 (1992 )), HE179-338 (YEp90-HE179-338; Pierrat, B. et al., Gene 143:193-200 (1994 )). From the yeast multicopy plasmid pBL1 ( LeDouarin, B. et al., Nucleic Acids Res.
  • TIF2 was expressed in yeast from the multicopy plasmid pAS3 (gift from B.LeDouann), which is a derivative of YEp90 containing the LEU2 marker.
  • Yeast PL3( ⁇ ) ( Pierrat, B. et al., Gene 119:237-245 (1992 )) transformants were grown exponentially in the presence or absence of ligand for about five generations in selective medium containing uracil. Yeast extracts were prepared and assayed for OMP decase activity as described previously ( Pierrat, B. et al., Gene 119:237-245 (1992 )).
  • TIF2.1 also stimulated the AF-2 activity of the liganded RXR ⁇ (DEF) region in yeast (FIG. 11, compare lanes 19 and 20). This enhancement was ligand-dependent; no activation via the RXR ⁇ (DEF) region was observed when the ER(C)-RXR ⁇ (DEF) chimera was coexpressed with TIF2.1 in the absence of ligand (FIG. 11, compare lanes 18 and 20). Again these observations parallel those made in HeLa and Cos-1 cells (see FIG. 12c).
  • yeast cells contain coactivators which only poorly mimic the action of the mammalian NR coactivators.
  • yeast cells apparently do not contain a CBP homologue, it will be interesting to investigate which yeast factor mediates the activity of TIF2.
  • GAL-TIF2.1 is a strong transactivator in yeast (our unpublished results).
  • Example 7 TIF2 NID inhibition of NR AF-2 activity
  • TIF2.1 fragment which contains both the NID and AD1 activation function, stimulates the ER AF-2 activity of the ER LBD transiently in Cos-1 cells (FIG. 12a, lanes 2 and 3; Voegel, J.J. et al., EMBO J. 15:3667-3675 (1996 )). That this stimulation was due to a direct interaction between the ER LBD and the NID of TIF2, was strongly suggested by the observation that overexpression of the TIF2.5 mutant which contains the isolated NID, but lacks AD1 (see FIG. 7a) prevented the stimulatory effect of TIF2.1 (FIG. 12a, compare lanes 3 and 4).
  • TIF2.5 overexpression also decreased the transactivation by the ER AF-2 which was presumably mediated through Cos-1 endogenous coactivators (FIG. 12a, compare lane 4 with lane 2), thus suggesting that these Cos-1 mediators either correspond to endogenous TIF2s, or interact with the ER holo-LBD through surfaces which are identical to, or in direct vicinity of, the TIF2 NID interaction surface.
  • TIF2 and TIF2.1 stimulatory activity for RXR ⁇ AF2 was observed in HeLa and Cos-1 cells when using the (17m) 5 -TATA-CAT reporter (FIG. 12c, compare lanes 3-6 and 11-14). This stimulatory effect was less marked with RAR ⁇ AF-2 and could be observed reproducibly only with the TIF2.1 fragment in Cos-1 cells (FIG. 12d, compare lane 10 with lanes 13 and 14; note that TIF2.1 is expressed at >10 fold higher levels than TIF2; data not shown).
  • the reporter plasmids (17m) 5 -TATA-CAT May, M. et al., EMBO J.
  • 17M5-G/CAT ((17m) 5 - ⁇ -globin-CAT; Durand, B. et al., EMBO J. 13:5370-5382 (1994 )) each contain five copies of the GAL4 response element in front of a simple TATA motif or of the ⁇ -globin promoter, respectively, upstream from the CAT reporter gene.
  • TIF2 or coactivators recognizing the TIF2 interacting surface on NR LBDs generally mediate the AF-2 function of NRs
  • the NID containing TIF2.5 should exert its dominant negative activity not only on ER, but also on other NRs, independently of the cellular context.
  • TIF2.5 was analyzed the effect of TIF2.5 on the AF-2 activity of ER, RXR ⁇ and RAR ⁇ in HeLa and in Cos-1 cells (FIGS. 12b-d).
  • TIF2.5 expression led to a dose-dependent inhibition of the NR AF-2 activity, indicating that the endogenously present mediators were competed out by the isolated overexpressed TIF2 NID, and strongly suggesting that TIF2 or transcriptional intermediary factors recognizing the same or overlapping surfaces mediate NR AF-2 activity in these transfected cells (FIGS. 12b-d, compare lane 2 with lanes 7 and 8; lane 10 with lanes 15 and 16).
  • TIF2 interacts with NRs through a surface (NID) that is critical for NR AF-2 activity, as expression of TIF2.5 which encompasses the NID blocked the ligand-induced activity of all tested NR AF-2s.
  • NID surface
  • TIF2 or other coactivators which interact with an overlapping, if not identical, holo-LBD surface, are essential to mediate the NR AF-2 activation function. This is in keeping with the presence of three NR box motifs in the TIF2 NID, and of at least one conserved LxxLL (SEQ ID NO:12) NR box motif in all coactivators described to date.
EP07101726A 1996-07-12 1997-07-11 Facteur intermédiaire transcriptionel 2 Expired - Lifetime EP1865060B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2124796P 1996-07-12 1996-07-12
EP97932575A EP0939810B1 (fr) 1996-07-12 1997-07-11 Facteur-2 intermediaire de la transcription

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP97932575A Division EP0939810B1 (fr) 1996-07-12 1997-07-11 Facteur-2 intermediaire de la transcription
EP97932575.0 Division 1998-01-22

Publications (2)

Publication Number Publication Date
EP1865060A1 true EP1865060A1 (fr) 2007-12-12
EP1865060B1 EP1865060B1 (fr) 2010-11-17

Family

ID=21803168

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97932575A Expired - Lifetime EP0939810B1 (fr) 1996-07-12 1997-07-11 Facteur-2 intermediaire de la transcription
EP07101726A Expired - Lifetime EP1865060B1 (fr) 1996-07-12 1997-07-11 Facteur intermédiaire transcriptionel 2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97932575A Expired - Lifetime EP0939810B1 (fr) 1996-07-12 1997-07-11 Facteur-2 intermediaire de la transcription

Country Status (7)

Country Link
US (2) US6268173B1 (fr)
EP (2) EP0939810B1 (fr)
AT (2) ATE353364T1 (fr)
DE (2) DE69740057D1 (fr)
DK (2) DK0939810T3 (fr)
ES (2) ES2354379T3 (fr)
WO (1) WO1998002455A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740057D1 (de) 1996-07-12 2010-12-30 Bristol Myers Squibb Co Transkriptionaler Intermediärfaktor 2
GB9708676D0 (en) * 1997-04-30 1997-06-18 Imp Cancer Res Tech Chemical compounds
GB2337329B (en) * 1997-04-30 2001-09-05 Imp Cancer Res Tech Inhibitors of nuclear protein/nuclear receptor interaction
WO1999032621A2 (fr) * 1997-12-22 1999-07-01 American Home Products Corporation Sequences d'acide nucleique codant des proteines de co-activateur de recepteur nucleaire et utilisation de ces sequences
AU2001264281A1 (en) * 2000-06-20 2002-01-02 Chugai Research Institute For Molecular Medicine, Inc. Novel transcription factor having zinc finger domain
DE10046647A1 (de) * 2000-09-20 2002-03-28 Ludwig Wildt Verfahren zur Bestimmung der Peptidhormon-Aktivitäten oder der Steroidhormon-Aktivitäten eines Materials oder Stoffgemisches
US6355483B1 (en) * 2000-11-27 2002-03-12 Isis Pharmaceuticals, Inc. Antisenses inhibition of SRC-2 expression
US20050202515A1 (en) * 2004-02-27 2005-09-15 Wyeth Functional method for generating or screening for ligands which modulate steroid hormone receptors
US7973135B2 (en) * 2006-07-12 2011-07-05 Oncotx, Inc. Compositions and methods for targeting cancer-specific transcription complexes
JP6357242B2 (ja) 2013-11-06 2018-07-11 ワット・フューエル・セル・コーポレイションＷａｔｔ Ｆｕｅｌ Ｃｅｌｌ Ｃｏｒｐ． 化学反応器へのガス状反応媒体の流れの管理のためのマニフォルドを備える燃料触媒部分酸化改質反応器

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023A1 (fr) 1983-04-08 1984-11-14 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0171496A2 (fr) 1984-08-15 1986-02-19 Research Development Corporation of Japan Procédé pour la production d'un anticorps monoclonal chimérique
EP0173494A2 (fr) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
EP0184187A2 (fr) 1984-12-04 1986-06-11 Teijin Limited Chaîne lourde d'immunoglobuline chimère souris-humaine et chimère de l'ADN codant celle-ci
US8602269B2 (en) 2009-09-14 2013-12-10 Guala Dispensing S.P.A. Trigger sprayer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8951191A (en) * 1990-10-29 1992-05-26 Dekalb Plant Genetics Isolation of biological materials using magnetic particles
US5840832A (en) 1994-10-21 1998-11-24 The Johns Hopkins University Transcription factor regulating MHC expression, CDNA and genomic clones encoding same and retroviral expression constructs thereof
DE69740057D1 (de) 1996-07-12 2010-12-30 Bristol Myers Squibb Co Transkriptionaler Intermediärfaktor 2

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023A1 (fr) 1983-04-08 1984-11-14 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0171496A2 (fr) 1984-08-15 1986-02-19 Research Development Corporation of Japan Procédé pour la production d'un anticorps monoclonal chimérique
EP0173494A2 (fr) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
EP0184187A2 (fr) 1984-12-04 1986-06-11 Teijin Limited Chaîne lourde d'immunoglobuline chimère souris-humaine et chimère de l'ADN codant celle-ci
US8602269B2 (en) 2009-09-14 2013-12-10 Guala Dispensing S.P.A. Trigger sprayer

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
BOCQUEL ET AL., NUCL. ACIDS RES., vol. 17, 1989, pages 2581 - 2595
BOCQUEL, NUCL. ACIDS RES., 1989
C.K. GLASS ET AL.: "Nuclear receptor coactivators", CURRENT OPINION IN CELL BIOLOGY, vol. 9, no. 2, April 1997 (1997-04-01), pages 222 - 232, XP002045759 *
CABILLY ET AL., PROC. NATL. ACAD SCI. USA, vol. 8I, 1984, pages 3273 - 3277
CATO ET AL., EMBO J., vol. 5, pages 2237
CAVAILLES, V. ET AL., PROC. NATL. ACAD SCI. USA, vol. 91, 1994, pages 10009 - 100013
CAVAILLÈS, V. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 10009 - 10013
DOUARIN ET AL., EMBO J, vol. 14, 1995, pages 2020 - 2033
GRONEMEYER ET AL., EMBO J., vol. 6, 1987, pages 3985 - 3994
H. HONG ET AL.: "GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors.", PROC. NATL. ACAD. SCI. USA, vol. 93, May 1996 (1996-05-01), pages 4948 - 4952, XP002045756 *
H. HONG ET AL.: "GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 5, May 1997 (1997-05-01), pages 2735 - 2744, XP002045758 *
HALACHMI, S. ET AL., SCIENCE, vol. 264, 1994, pages 1455 - 1458
HARLOW; LANE: "ANTIBODIES: A LABORATORY MANUA", 1988, COLD SPRING HARBOR LABORATORY
J.J. VOEGEL ET AL.: "TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors", THE EMBO JOURNAL, vol. 15, no. 14, 15 July 1996 (1996-07-15), pages 3667 - 3675, XP002045757 *
JACQ, X. ET AL., CELL, vol. 79, 1994, pages 107 - 117
KUMAR ET AL., CELL, vol. 51, 1987, pages 941 - 951
KUROKAWA, R. ET AL., NATURE, vol. 377, 1995, pages 451 - 454
LE DOUARIN, B. ET AL., EMBO J., vol. 14, 1995, pages 2020 - 2033
LIU ET AL., PROC. NATL. ACAD SCI. USA, vol. 84, 1987, pages 3439 - 3443
MAY, M. ET AL., EMBO J., vol. 15, 1996, pages 3093 - 3104
MENGUS, G. ET AL., GENES & DEV., vol. 11, 1997, pages 1381 - 1395
NEUBERGER ET AL., NATURE, vol. 3, no. 14, 1985, pages 268 - 270
S.A. OÑATE ET AL.: "Sequence and characterization of a coactivator for the Steroid Hormone Receptor Superfamily", SCIENCE, vol. 270, 24 November 1995 (1995-11-24), pages 1354 - 1357, XP002045755 *
SCHULMAN, IG. ET AL., MOL. CELL. BIOL., vol. 16, 1996, pages 3807 - 3813
SUN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 214 - 218
TORCHIA J ET AL: "The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 387, no. 6634, 12 June 1997 (1997-06-12), pages 677 - 684, XP002088153, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
US6268173B1 (en) 2001-07-31
US20020106727A1 (en) 2002-08-08
EP0939810A2 (fr) 1999-09-08
DE69740057D1 (de) 2010-12-30
EP1865060B1 (fr) 2010-11-17
DK1865060T3 (da) 2011-03-07
ATE488589T1 (de) 2010-12-15
ES2281105T3 (es) 2007-09-16
DE69737326D1 (de) 2007-03-22
US6861508B2 (en) 2005-03-01
WO1998002455A2 (fr) 1998-01-22
DE69737326T2 (de) 2007-11-22
ES2354379T3 (es) 2011-03-14
DK0939810T3 (da) 2007-04-10
EP0939810B1 (fr) 2007-02-07
ATE353364T1 (de) 2007-02-15
WO1998002455A3 (fr) 1999-04-08

Similar Documents

Publication Publication Date Title
Jacq et al. Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor
Jung et al. Novel transcription coactivator complex containing activating signal cointegrator 1
May et al. Human TAF (II28) promotes transcriptional stimulation by activation function 2 of the retinoid X receptors.
US5639616A (en) Isolated nucleic acid encoding a ubiquitous nuclear receptor
US20060287503A1 (en) Retinoid X receptor-interacting polypeptides and related molecules and methods
EP1865060B1 (fr) Facteur intermédiaire transcriptionel 2
Elaroussi et al. The avian vitamin D receptors: primary structures and their origins.
US6635429B1 (en) Heterodimeric nuclear receptors proteins, genes encoding same, and usage thereof
US7314747B1 (en) SMRT co-repressors, transcriptional co-repressors that interact with nuclear hormone receptors
Le Douarin et al. Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors (mediators)
Gronemeyer Transcription activation by nuclear receptors
EP0729975B1 (fr) Proteine ecdn et adn codant cette proteine
US7026125B1 (en) Heterodimers of retinoid X receptors (RXRS) and other steroid hormone receptors
US7312066B2 (en) Nucleic acid molecules encoding NRC interacting factor-1 (NIF-1)
EP1364018A2 (fr) Recepteurs d'hormone nucleaire humaine isoles, molecules d'acides nucleiques codant des recepteurs d'hormone nucleaire humaine, et utilisations
WO2000065052A9 (fr) «bridge-1», un facteur de transcription
WO2002070697A1 (fr) Recepteur nucleaire l67 de mammifere et ses procedes d'utilisation
EP1530586A2 (fr) Proteines humaines secretees isolees, molecules d'acides nucleiques codant pour des proteines humaines secretees et utilisations associees

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0939810

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20080327

17Q First examination report despatched

Effective date: 20080526

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LUTZ, YVES

Inventor name: GRONEMEYER, HINRICH

Inventor name: VOEGEL, JOHANNES

Inventor name: CHAMBON, PIERRE

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS

Owner name: UNIVERSITE DE STRASBOURG

Owner name: BRISTOL-MYERS SQUIBB COMPANY

AC Divisional application: reference to earlier application

Ref document number: 0939810

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69740057

Country of ref document: DE

Date of ref document: 20101230

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101117

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101117

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101117

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110818

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69740057

Country of ref document: DE

Effective date: 20110818

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20160609

Year of fee payment: 20

Ref country code: ES

Payment date: 20160613

Year of fee payment: 20

Ref country code: LU

Payment date: 20160630

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20160613

Year of fee payment: 20

Ref country code: FR

Payment date: 20160613

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160720

Year of fee payment: 20

Ref country code: IE

Payment date: 20160711

Year of fee payment: 20

Ref country code: CH

Payment date: 20160712

Year of fee payment: 20

Ref country code: DE

Payment date: 20160705

Year of fee payment: 20

Ref country code: GB

Payment date: 20160706

Year of fee payment: 20

Ref country code: DK

Payment date: 20160712

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20160630

Year of fee payment: 20

Ref country code: SE

Payment date: 20160712

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69740057

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20170711

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20170710

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 488589

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170711

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170711

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170710

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170712